Ym Biosciences Inc Sample Contracts

AutoNDA by SimpleDocs
RECITALS
Shareholders' Agreement • May 18th, 2004 • Ym Biosciences Inc

Between: York Medical Inc.("YM"), a company incorporated under the laws of the Province of Ontario, Canada, CIMYM Inc., a company incorporated under the laws of Barbados ("CIMYM") and CIMAB S.A. ("CIMAB") a Cuban company incorporated under the laws of the Republic of Cuba, representing Centro de Inmunologia Molecular ("CIM").

EXHIBIT 4.20 CONFIDENTIAL
Supply Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • England and Wales
EXHIBIT 99.2 MERGER AGREEMENT
Merger Agreement • May 3rd, 2005 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
BY-
License Agreement • May 18th, 2004 • Ym Biosciences Inc • Saskatchewan
YM BIOSCIENCES INC. And CIBC MELLON TRUST COMPANY As Rights Agent SHAREHOLDER RIGHTS PLAN AGREEMENT
Shareholder Rights Plan Agreement • December 11th, 2007 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario

THIS AGREEMENT dated as of the 22nd day of October, 2007 between YM BioSciences Inc. (the “Corporation”), a corporation continued under the Companies Act (Nova Scotia), and CIBC Mellon Trust Company, a trust company incorporated under the laws of Canada, as Rights Agent (the “Rights Agent”), which term shall include any successor Rights Agent hereunder.

EXHIBIT 4.4
Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • Manitoba
ARRANGEMENT AGREEMENT AMONG GILEAD SCIENCES, INC. - AND - 3268218 NOVA SCOTIA LIMITED - AND – YM BIOSCIENCES INC. DECEMBER 12, 2012
Arrangement Agreement • December 12th, 2012 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario

WHEREAS the Parent desires to acquire all of the Common Shares (as hereinafter defined) through its wholly-owned subsidiary, the Purchaser;

EXHIBIT 4.20 CONFIDENTIAL
Supply Agreement • August 19th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • England and Wales
Exhibit 4.3 (1) CIMYM, INC. (2) CIMAB S.A. AND
Development and Licence Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • London
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD.
Clinical Research Services Agreement • September 24th, 2004 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario
9,436,471 Shares YM BIOSCIENCES INC. Common Shares (without nominal or par value) PLACEMENT AGENT AGREEMENT
Placement Agent Agreement • February 17th, 2006 • Ym Biosciences Inc • Pharmaceutical preparations • New York
AutoNDA by SimpleDocs
EXHIBIT 4.17
Ym Biosciences Inc • May 18th, 2004

We refer to the assignment and assumption agreement dated as of November 22, 1995 among CBQYM INC. and York Medical Inc. ("YMI") pursuant to which YMI assigned to CBQYM INC. all of YMI's right, title and interest in and to the Licensing Agreement (as defined therein).

AGREEMENT THIS AGREEMENT, effective November 2, 2000, is entered into
Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Manitoba
November 23, 1995 CIMYM INC. 5045 Orbitor Drive Building 11, Suite 400 Mississauga, Ontario L4W 4Y4 Dear Sirs: We refer to the assignment and assumption agreement dated as of November 22, 1995 among CIMYM INC. and York Medical Inc. ("YMI") pursuant to...
Ym Biosciences Inc • May 18th, 2004

We refer to the assignment and assumption agreement dated as of November 22, 1995 among CIMYM INC. and York Medical Inc. ("YMI") pursuant to which YMI assigned to CIMYM INC. all of YMI's right, title and interest in and to the Licensing Agreement (as defined therein).

MASTER SERVICES AGREEMENT
Master Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario

This Master Services Agreement ("Agreement") is entered into as of May 17th, 2007 (the "Effective Date") by and between YM Biosciences Inc., a Canadian corporation with an office at 5045 Orbitor Drive, Bldg. 11, Suite 400, Mississauga, Ontario L4W 4Y4 (collectively with its Affiliates hereinafter the "YMB") and Allphase Clinical Research Services Inc., having offices at 19 Camelot Drive, Ottawa, Ontario, K2G 5W6 (collectively with its Affiliates hereinafter "ALLPHASE"). YMB and ALLPHASE are referred to singly as "Party" and jointly as "Parties" throughout this Agreement.

YM BIOSCIENCES INC. 7,750,000 Common Shares Controlled Equity Offeringsm Sales Agreement
Sales Agreement • April 26th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • New York

YM BIOSCIENCES INC. (the “Company”), a corporation continued under the Nova Scotia Companies Act (the “NSCA”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“CF&Co”), as follows:

Agreement Implementation agreement YM BioSciences Inc. Cytopia Limited rodd.levy@freehills.com 101 Collins Street Melbourne VIC 3000 Australia GPO Box 128A Melbourne VIC 3001 Australia Sydney Melbourne Perth Brisbane Singapore Telephone +61 3 9288...
Implementation Agreement • October 8th, 2009 • Ym Biosciences Inc • Pharmaceutical preparations • Victoria

YM may not rely on the words or conduct of any Scheme Shareholder as a waiver of any right unless the waiver is in writing and signed by the Scheme Shareholder granting the waiver.

AGREEMENT AND PLAN OF MERGER BY AND AMONG YM BIOSCIENCES INC., YM BIOSCIENCES USA INC., YM BIOSCIENCES U.S. OPERATIONS INC., EXIMIAS PHARMACEUTICAL CORPORATION AND ORBIMED ADVISORS, LLC, AS STOCKHOLDER REPRESENTATIVE April 13, 2006
Agreement and Plan of Merger • September 22nd, 2008 • Ym Biosciences Inc • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into on April 13, 2006, by and among YM BioSciences Inc., a corporation existing under the laws of Nova Scotia, Canada (“Acquiror”), YM BioSciences USA Inc., a Delaware corporation and wholly-owned subsidiary of Acquiror, (“YM BioSciences USA”), YM BioSciences U.S. Operations Inc., a Delaware corporation and wholly-owned subsidiary of YM BioSciences USA (“Merger Sub”), Eximias Pharmaceutical Corporation, a Delaware corporation (“Target”), and OrbiMed Advisors, LLC on behalf of the Series D Stockholders (in such capacity referred to as the “Stockholder Representative”). Certain capitalized terms used in this Agreement are defined in Exhibit A hereto.

EXHIBIT 4.18 EXCLUSIVE INTERNATIONAL SALES, MARKETING MANUFACTURING AND ADMINISTRATIVE AGREEMENT (hereinafter called the "Agreement")
Manufacturing and Administrative Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD. YB1002-203Taxotere
Clinical Research Services Agreement • September 22nd, 2008 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario

This Clinical Research Services Agreement (this Agreement) is made and entered into effective as of 10 December 2004 (the “Effective Date”), by and between YM BIOSCIENCES, INC. (hereafter “YM”), a Canadian corporation, with its principal office at 5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada, and PHARM-OLAM INTERNATIONAL Ltd. (hereafter “POI”), a Texas limited partnership, with its principal office at 450 N Sam Houston Parkway, Suite 250, Houston, TX 77060, United States.

between
And Administrative Agreement • May 18th, 2004 • Ym Biosciences Inc • Ontario
CLINICAL RESEARCH SERVICES AGREEMENT BETWEEN YM BIOSCIENCES, INC. AND PHARM- OLAM INTERNATIONAL LTD. YB1002-203Taxotere
Clinical Research Services Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • Ontario

This Clinical Research Services Agreement (this Agreement) is made and entered into effective as of 10 December 2004 (the “Effective Date”), by and between YM BIOSCIENCES, INC. (hereafter “YM”), a Canadian corporation, with its principal office at 5045 Orbitor Drive, Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada, and PHARM-OLAM INTERNATIONAL Ltd. (hereafter “POI”), a Texas limited partnership, with its principal office at 450 N Sam Houston Parkway, Suite 250, Houston, TX 77060, United States.

and License Agreement Relating to Nimotuzumab (TheraCIM h-R3)
License Agreement • March 4th, 2010 • Ym Biosciences Inc • Pharmaceutical preparations • London
Time is Money Join Law Insider Premium to draft better contracts faster.